Ultragenyx Pharmaceutical RARE Product — Sales Reserves Payments

Similar metrics at other companies

USFDSelf Insurance Reserve Payments

$32M+5.8%

ALKSProduct Discounts — Accrued Sales Discounts Allowances And Reserves

$18.7M+21.8%

MDGLRebates, Co-Pay Assistance, Returns, and Other — Gross To Net Adjustments Reserve Credits And Payments Made

$94.36M—

PLUSSales Returns Reserve For Sales Returns

$2.68M-35.5%

NLYPayments For Securities Purchased Under Agreements To Resell

$54.31B-68.5%

ALKSOther — Accrued Sales Discounts Allowances And Reserves

$39.62M+97.3%

Questions, answered.

What is Ultragenyx Pharmaceutical's product — sales reserves payments?

Ultragenyx Pharmaceutical (RARE) reported product — sales reserves payments of $7.5M in Q4 2025.

How has Ultragenyx Pharmaceutical's product — sales reserves payments changed year-over-year?

Ultragenyx Pharmaceutical's product — sales reserves payments increased by 42.9% year-over-year, from $5.25M to $7.5M.

What is the long-term trend for Ultragenyx Pharmaceutical's product — sales reserves payments?

Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's product — sales reserves payments has grown at a 48.8% compound annual growth rate (CAGR), from $6.12M to $30M.

What does product — sales reserves payments mean?

This represents the actual cash outflows made to settle obligations related to sales reserves, such as rebates or returns. It provides insight into the cash-flow impact of the company's commercial pricing and contracting strategies. Comparing payments to provisions helps investors evaluate the accuracy of the company's historical revenue estimation processes.